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cholesterol, low‑density lipoprotein cholester‑
ol [LDL‑C], high‑density lipoprotein cholesterol 
[HDL‑C], and triglyceride levels), as well as use 
of lipid‑lowering drugs and their doses. For each 
patient, we performed DCLN scoring and identi‑
fied patients with a possible (score, 3–5), proba‑
ble (score, 6–8), or definite (score >8) diagnosis 
of FH.4 Data regarding the clinical signs of lipid 
accumulation in the tissue, as well as family his‑
tory of elevated LDL‑C levels were not available 
for all patients, so in these cases missing infor‑
mation was counted as zero in DLCN criteria. In 
addition, the categories “definite FH” and “prob‑
able FH” were combined into “potential FH,” as 
it was done in a previous study.2 No genetic test‑
ing was performed, so the final classification was 
based only on phenotype characteristics. The Ja‑
giellonian University Bioethical Committee was 
notified about the registry.
Statistical analysis For continuous variables, data 
were presented as a mean with SD and as a median 
with the first and third quartiles. These continu‑
ous data were compared using the Wilcoxon test. 
Categorical data were presented as numbers and 
percentages, and were compared using the Pear‑
son χ2 test. All statistical analyses were performed 
using the JMP®, Version 14.0.0. SAS Institute Inc., 
2018 (Cary, North Carolina, United States). A P val‑
ue of less than 0.05 was considered significant. No 
formal power calculation was performed.
Results and discussion Based on the collected 
data of hospitalized patients, there were 341 con‑
secutive individuals for whom it was possible to 
calculate the DCLN score. There were 5 cases of 
definite FH (DLCN score >8 points, 1.5%). Poten‑
tial FH (definite and probable) was more frequent 
Introduction Heterozygous familial hypercho‑
lesterolemia (FH) is the most common monogen‑
ic dyslipidemia causing premature ischemic heart 
disease.1 The prevalence of FH in the general Polish 
population has been estimated at 1 in 250 adults; 
moreover, the number of patients with definite FH 
is relatively small: in a meta ‑analysis of 6 studies, 
involving more than 37 000 of patients, definite 
FH was diagnosed only in 7 patients.2 Important‑
ly, despite the fact that the appropriate treatment 
may be administered to reduce the risk of prema‑
ture atherosclerosis, only selected patients with 
FH are identified early and properly diagnosed.3 In 
most cases, the diagnosis of FH is based on Dutch 
Lipid Clinic Network (DLCN) criteria.4 Data on 
the prevalence of FH in patients with acute coro‑
nary syndromes (ACSs) are still lacking. Thus, we 
aimed to evaluate the prevalence of clinical FH 
among patients presenting with ACS.
Methods Data on consecutive patients hospi‑
talized in the 2nd Department of Cardiology and 
Cardiovascular Interventions, University Hospi‑
tal in Krakow, between June 1, 2017, and June 30, 
2018, due to ACS were collected retrospectively in 
a dedicated database. Demographic and clinical 
data, including traditional risk factors (arterial 
hypertension, diabetes mellitus, smoking), med‑
ical history (cerebrovascular and cardiovascular 
incidents), and family history of premature ath‑
erosclerosis were recorded. During data collec‑
tion, we excluded all patients for whom the in‑
formation regarding the secondary cause of hy‑
percholesterolemia (untreated hypothyroidism, 
nephrotic syndrome, cholestasis, hypopituita‑
rism, or use of atypical antipsychotic drugs) was 
present in medical history. We also collected bio‑
chemical data including serum lipid profile (total 
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of patients with at least a possible diagnosis of 
FH according to DLCN criteria are shown in TABLE 1.
Our major finding is that the prevalence of 
FH diagnosed using the DLCN criteria is more 
than 4% among patients with ACS. To our best 
(15 patients, 4.4%). Possible FH was diagnosed 
in 30 patients (8.8%). The estimated preva‑
lence of FH in patients with ACS was 1 in 23 pa‑
tients, considering patients with the probable 
and definite diagnosis of FH. The characteristics 
TABLE 1 Characteristics of patients presenting with acute coronary syndrome with possible and potential 
(probable and definite) familial hypercholesterolemia according to Dutch Lipid Clinic Network (DLCN) criteria
Parameter Possible FH  
(n = 30)
Potential FH (probable 
and definite) (n = 15)
P value
Age, y Mean (SD) 64.97 (10.15) 56.27 (13.19) 0.04a
Median (IQR) 66.50 (56.00; 73.50) 61.00 (45.00; 64.00)
Weight, kg Mean (SD) 82.58 (12.31) 80.47 (20.35) 0.66a
Median (IQR) 80.00 (75.25; 94.25) 81.00 (60.00; 94.00)
Height, cm Mean (SD) 168.50 (8.69) 170.67 (7.38) 0.49a
Median (IQR) 168.50 (161.5; 177.25) 170.00 (167.00; 176.00)
DLCN score, points Mean (SD) 3.67 (0.88) 9.00 (3.25) 0.0001a
Median (IQR) 3.00 (3.00; 5.00) 8.00 (7.00; 11.00)
BSA, m2 Mean (SD) 1.93 (0.18) 1.92 (0.26) 0.63a
Median (IQR) 1.97 (1.81; 2.04) 1.94 (1.64; 2.07)
TC, mmol/l Mean (SD) 5.35 (1.04) 6.64 (2.21) 0.02a
Median (IQR) 5.35 (4.58; 5.85) 6.35 (5.00; 7.30)
LDL‑C, mmol/l Mean (SD) 3.34 (0.94) 4.55 (2.02) 0.01a
Median (IQR) 3.15 (2.73; 3.73) 4.30 (3.30; 5.20)
HDL‑C, mmol/l Mean (SD) 1.18 (0.28) 1.16 (0.33) 0.75a
Median (IQR) 1.17 (0.96; 1.44) 1.11 (0.89; 1.41)
TG, mmol/l Mean (SD) 1.83 (0.94) 2.13 (0.96) 0.29a
Median (IQR) 1.72 (1.09; 2.48) 1.92 (1.37; 2.91)
Men, n (%) 18 (60) 9 (60) 0.99b
Hypertension, n (%) 25 (83.3) 11 (73.3) 0.43b
Diabetes, n (%) 9 (30) 4 (26.7) 0.82b
Smoking, n (%) 8 (26.7) 6 (40) 0.36b
Stroke / TIA, n (%) 1 (3.3) 0 (0) 0.47b
Chronic kidney disease, n (%) 4 (13.3) 1 (6.7) 0.50b
CAD – previous PCI, n (%) 11 (36.7) 4 (26.7) 0.50b
CAD – previous CABG, n (%) 5 (16.7) 2 (13.3) 0.77b
Carotid artery disease, n (%) 4 (13.3) 1 (6.7) 0.50b
Atrial fibrillation, n (%) 2 (6.7) 0 (0) 0.31b
Family history of premature CAD, n (%) 4 (13.3) 6 (40) 0.04b
Ezetimibe, n (%) 1 (3.3) 5 (33.3) 0.01b
Maximal statin dose (atorvastatin, 80 mg, 
or rosuvastatin, 40 mg), n (%)
3 (10) 10 (66.7) 0.001b
a Wilcoxon test;  b Pearson χ2 test
Abbreviations: BSA, body surface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; FH, familial 
hypercholesterolemia; HDL‑C, high‑density lipoprotein cholesterol; IQR, interquartile range; LDL‑C, low‑density lipoprotein cholesterol; 
PCI, percutaneous coronary intervention; TC, total cholesterol; TG, triglycerides; TIA, transient ischemic attack
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a therapeutic goal, we should consider new specif‑
ic drugs. The PCSK9 inhibitors have a quite high 
level of recommendations (IIa A), not only among 
patients with FH, but in all individuals who are 
judged to be at a very high risk.10 Due to the high 
cost of the therapy, this treatment has not been 
widely available so far. However, the Polish Na‑
tional Health Fund has already prepared the ded‑
icated drug program for patients with the diagno‑
sis of FH, and this treatment option may be imple‑
mented in a selected group of patients.11 At pres‑
ent, PCSK9 inhibitors are available for adult pa‑
tients with a diagnosis of definite FH, who have 
LDL levels above 160 mg/dl on the maximal stan‑
dard lipid ‑lowering therapy.
In conclusion, our study allows better under‑
standing of the magnitude of the FH problem 
in young patients presenting with ACS, which 
may result in more careful screening and opti‑
mization of lipid‑lowering treatment in every‑
day practice.
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knowledge, this is the first estimation of FH prev‑
alence in ACS patients admitted for intervention‑
al treatment in Poland. This value is over 10‑fold 
higher than for the general Polish population us‑
ing similar diagnostic methods.2 Thus, FH might 
be considered as a significant risk factor of ACS 
and should be routinely screened.
Similarly, the prevalence of probable or def‑
inite FH according to the DLCN criteria com‑
bined with Simon Broome criteria was estimated 
at 1.6% in a multicenter cohort study of 4778 pa‑
tients with ACS in Switzerland.5 When consid‑
ering only younger adults with premature ACS, 
FH diagnosis reached 4.8%. Also in our study 
the diagnosis of potential FH was more com‑
mon in younger adults, which is in line with re‑
ports from the general Polish population, where 
the occurrence of FH was the highest in the age 
group of 45 to 54 years in men and 55 to 64 years 
in women.2 Despite young age, we noticed that 
more than 30% of patients had percutaneous 
coronary interventions in the past. It may un‑
derline the value of attentive screening and ap‑
plication of primary prevention of coronary ar‑
tery disease in this group of patients. Of note, 
previous investigators have already drawn at‑
tention to suboptimal detection and treatment 
of patients with FH in Poland.6
Considering the high incidence of FH among 
patients with ACS diagnosis, we are convinced 
that dedicated registries of patients with FH 
should be launched in every cardiac ward. First 
of all, it may expand the possibilities of diagnosis 
of patients with FH. Moreover, when new lipid‑
‑lowering drugs enter the market (PCSK9 inhibi‑
tors) and the Polish National Health Fund intro‑
duces drug programs that will increase the avail‑
ability of these previously costly therapies, we 
believe that it will be worth screening for pa‑
tients who may benefit from new treatment op‑
tions. In this way, the risk of cardiovascular dis‑
eases may be diminished, and the quality of pa‑
tients’ life may be significantly improved.
One of the limitations of our study is the lack 
of genetic testing to identify monogenic muta‑
tions associated with FH. From the clinical per‑
spective, the lack of genetic diagnostics implies 
that cascade diagnostics of families of patients 
with ACS is unavailable. However, our primary 
goal was to estimate the prevalence of clinical 
FH among ACS patients in order to optimize lip‑
id‑lowering treatment. Importantly, each patient 
with the ACS diagnosis should be treated with 
high‑dose statins if there are no contraindica‑
tions.7,8 The diagnosis of the potential FH result‑
ed in the escalation of statin treatment combined 
with ezetimibe much more frequently than in 
the group with possible FH. This approach stayed 
in accordance with the 2016 European Society 
of Cardiology and European Atherosclerosis So‑
ciety guidelines for the management of dyslip‑
idemias.9 At any time, when we do not achieve 
